Category: Medicine

An artificial intraocular lens (IOL) is essential for people with cataracts, a condition where the eye’s natural lens becomes cloudy, impairing vision. IOLs are also used to correct refractive errors such as myopia (near-sightedness), hyperopia (far-sightedness), and presbyopia (the gradual loss of the eye’s ability to focus on close objects, a normal part of aging).

“For the first time, we have developed a resin that can be used to print ocular devices directly,” said Dr. Aram Saeed, Associate Professor in Healthcare Technologies at UEA’s School of Pharmacy. “While still in the early stages, the ability to 3D print these lenses could significantly enhance eye care for patients by offering unprecedented levels of customization and design precision, potentially leading to better clinical outcomes.”

The EU-funded project IV-Lab, coordinated by the Istituto Italiano di Tecnologia (IIT-Italian Institute of Technology), has officially launched. This innovative project aims to develop a multi-sensing device that can be implanted into blood vessels, such as peripheral veins or arteries, to monitor various body parameters and the overall health of individuals. Once implanted in patients with cardiovascular diseases, the microsensor system will create a versatile platform capable of detecting both hemodynamic and biochemical parameters.

The IV-Lab project, which stands for “In-vessel implantable smart sensing device for personalized medicine,” has secured more than 4 million euros from the European Innovation Council (EIC) under the Horizon Europe program for research and innovation. Coordinated by Virgilio Mattoli, a researcher at IIT in Pisa, the project involves several IIT groups: the Soft Micro-Electronic Materials Group at the Center for Materials Interfaces (CMI) in Pontedera, the Printed and Molecular Electronics group in Milan, and the Electronic Design Laboratory in Genoa.

Sony, the Tokyo-based electronics giant, is stepping into the surgical robotics arena with its innovative microsurgery assistance robot. Designed to aid in precision microsurgical procedures, this robot marks Sony’s ambitious entry into a rapidly evolving field.

Sony’s newly developed robot is engineered to handle the delicate and precise tasks required in microsurgery, such as working on veins and nerves. The system includes a highly sensitive control device that tracks the movements of a surgeon’s hands and fingers, replicating these movements on a small surgical instrument. This instrument mimics the dexterity and range of motion of the human wrist, enhancing the precision and efficiency of surgical procedures.

Enable Injections, Inc. (“Enable”), a leader in wearable drug delivery technology, has announced an expanded partnership with Roche. This collaboration aims to accelerate the development and commercialization of innovative treatment options by leveraging Enable’s enFuse® platform.

The enFuse platform is a cutting-edge wearable device designed to deliver large volumes of medication subcutaneously, eliminating the need for traditional intravenous (IV) administration. Key features of the enFuse technology include:

Japanese scientists are set to commence the world’s first clinical trials for a groundbreaking “tooth regrowth medicine” at Kyoto University Hospital, according to The Mainichi.

In September, the startup Toregem Biopharma will begin testing what is believed to be the first treatment capable of regrowing teeth. This innovative therapy aims to address congenital anodontia, a condition where individuals are born without some or all of their teeth. Toregem Biopharma, affiliated with Kyoto University, announced the clinical trials on Thursday and aims to bring the antibody drug to market by 2030. The company also hopes to eventually offer this treatment to individuals who lose teeth later in life.

The emergence of RNA viruses like SARS-CoV-2 underscores the urgent need for innovative strategies to combat infectious diseases. While RNA-targeting tools such as CRISPR/Cas13 hold promise, their effectiveness in the cytoplasm – where many RNA viruses replicate – has been limited. Now, scientists from Helmholtz Munich and the Technical University Munich (TUM) have introduced a groundbreaking solution: Cas13d-NCS. This molecular tool enables CRISPR RNA molecules within the nucleus to move to the cytoplasm, enhancing their efficacy in neutralizing RNA viruses.

Published in Cell Discovery, this advancement heralds a new era in precision medicine and proactive viral defense strategies, crucial for addressing ongoing and future global health threats posed by RNA viruses.

Dick McCarthy, an 82-year-old who had always been physically active, found himself sidelined by excruciating knee pain due to bone-on-bone arthritis. Traditional knee replacement surgery seemed daunting, given the lengthy rehabilitation involved. However, upon discovering the Regenerative Biologics Institute (RBI) in Vero Beach, McCarthy found hope in stem cell therapy.

McCarthy’s decision to undergo stem cell therapy was informed by a comprehensive consultation and evaluation with Jason Griffeth, M.S., the clinical director at RBI. The procedure, completed on a Saturday afternoon, was minimally invasive, allowing McCarthy to return to his daily routine immediately. Remarkably, within days, he was back on the pickleball court, experiencing restored comfort and mobility.

In the realm of cellular therapies, groundbreaking advancements have propelled treatments from theoretical concepts to clinical realities. Over the past decade, two pivotal technologies, chimeric antigen receptors (CAR) and genome editing, have spearheaded the development of revolutionary CAR T cell therapies for leukemia and lymphoma. These therapies, engineered through virus-mediated gene insertion ex vivo, empower T cells with synthetic receptors to recognize and eliminate tumor-specific antigens post-transplantation.

While genome editing, particularly utilizing clustered regularly interspaced short palindromic repeats (CRISPR), has shown promise in enhancing CAR T cell therapies, it also presents unique challenges. The permanent nature of DNA editing poses safety and efficacy concerns, prompting the need for innovative solutions. Addressing this need, bioengineer Lei (Stanley) Qi and physician immunologist Crystal Mackall at Stanford University have introduced multiplexed effector guide arrays (MEGA), an RNA editing tool designed to circumvent the limitations of DNA editing.

Attention deficit hyperactivity disorder (ADHD) affects millions worldwide, with profound impacts on both children and adults. Characterized by inattention, hyperactivity, and impulsivity, ADHD can significantly hinder academic and social functioning. While its genetic basis has long been acknowledged, identifying specific genes involved has remained a challenge. However, recent strides in research have illuminated a key player: the CDH2 gene.

Israeli scientists from Ben-Gurion University of the Negev and Soroka-University Medical Center have made a groundbreaking discovery, identifying CDH2 as a pivotal gene implicated in ADHD. CDH2 encodes N-cadherin, a protein essential for brain synapse activity and formation. Through meticulous investigation, researchers found that mutations in CDH2 disrupt synaptic activity, influencing molecular pathways and dopamine levels in brain regions associated with ADHD.

A recent study published in the Journal of Cell Biology has illuminated the crucial role played by the enzyme GCN5 in maintaining the expression of key structural proteins in skeletal muscle. These proteins are essential for fundamental functions such as breathing, posture, and locomotion. Led by an international team of researchers from the Faculty of Medicine at the University of Ottawa, this discovery holds promise for future therapeutics targeting muscle degeneration caused by factors like aging, cancer, and muscular dystrophy.

Over a span of approximately five years, Dr. Keir Menzies, a molecular biologist at the Faculty of Medicine, and his team conducted experiments involving a muscle-specific mouse “knockout” of GCN5. This enzyme, known for regulating various cellular processes, was disrupted to understand its impact on muscle health during physical stress, such as downhill treadmill running.

Researchers at Penn State have unveiled a groundbreaking wireless charging device with the potential to significantly enhance the powering capability of next-generation implantable biomedical devices. The device, outlined in the journal Energy & Environmental Science, uniquely harvests energy from both magnetic fields and ultrasound sources simultaneously, demonstrating high efficiency within the safety limits for human tissue.

This innovative technology marks a crucial advancement for implantable devices such as pacemakers, insulin pumps, and neurostimulators. Unlike conventional devices that rely on batteries or wired charging, the new wireless charging device opens avenues for miniaturized, millimeter-sized bioelectronic devices that can be easily implanted. The researchers anticipate distributed networks of sensors and actuators, capable of measuring and manipulating physiological activity throughout the body with minimal risks and interference in daily activities.